Approval of first ‘RNA interference’ drug – why the excitement?

Jing Li, Ju Liu, Xuemei Zhang, Valerie A. Clausen, Chris Tran, Michael Arciprete, Qianfan Wang, Carrie Rocca, Lihua Guan, Guodong Zhang, Diana Najarian, Yuanxin Xu, Pete Smith, Jing‐Tao Wu, Saeho Chong

Authors

Thomas D Schmittgen
University of Florida

Discussion(0)

No comments yet. Be the first to comment.

Open reviews(0)

Public, signed peer feedback on this preprint.

No reviews yet.

Publication Info

DOI: 10.64628/aai.gvf6xrxjd
Year: 2018
Published: —
Language: en

Preprint Details

Link Of The Paper: https://doi.org/10.64628/aai.gvf6xrxjd

Timeline

Created:June 19, 2026

Article2023

Mechanistic exploration of autophagy and aging by RNA interference

Hui Pan, Oliver Kepp, Guido Guido Kroemer

Article2019

Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration

De Clercq Erik

Letter2020

A genome-wide RNA interference screen disentangles the Golgi tropism of LC3

Giulia Cerrato, Oliver Kepp, Allan Sauvat, Guido Guido Kroemer

Article2013

MicroRNA or NMD: Why Have Two RNA Silencing Systems?

Zhenguo Zhang, Landian Hu, Xiangyin Kong